Literature DB >> 27363417

Timing and long-term prognosis of recurrent MI after primary angioplasty : Stent thrombosis vs. non-stent-related reinfarction.

A Viveiros Monteiro1, R Ramos2, A Fiarresga2, L de Sousa2, D Cacela2, L Patrício2, L Bernardes2, C Soares2, R Cruz Ferreira2.   

Abstract

BACKGROUND: In patients recovering from an ST-segment elevation myocardial infarction (STEMI), it is not clear whether the negative impact of stent thrombosis (ST) is different from a non-stent-related recurrent myocardial infarction (NSRMI). This study sought to assess the long-term incidence and prognostic impact of recurrent myocardial infarction (MI) after percutaneous coronary intervention (PCI) for STEMI by comparing outcomes of ST versus NSRMI. PATIENTS AND METHODS: From 2001 to 2007, 1025 patients undergoing PCI for STEMI were prospectively followed up. Patients with ST, with NSRMI, and those free from recurrent MI were compared regarding mortality and major adverse cardiac and cerebrovascular events (MACCE).
RESULTS: Recurrent MI decreased from 37 events per 1000 person/months in the first month to 3.3 events per 1000 person/months after the first year. The cumulative 5‑year incidence of ST and NSRMI was 5.27 % and 13.2 %, respectively. MACCE at 60 months after recurrence were not significantly different for patients with reinfarction but were significantly higher than for patients free from any recurrent MI (both log-rank p < 0.001). However, the cumulative all-cause death rate did not differ between the three groups (27.8 vs. 26.7 vs. 23.0 %). Compared with ST occurring in the first 30 days after PCI for STEMI, early NSRMI was associated with a significantly reduced risk for all-cause death (HR, 0.21; 95 % CI, 0.33-3.30) but this association did not persist for recurrent MIs occurring in the late (HR, 1.05; 95 % CI, 0.33-3.30) or very late follow-up periods.
CONCLUSION: Although ST was associated with a significant increase in adverse events in the early recovery period, in the long term, MACCE and all-cause mortality rates were comparable to those for NSRMI.

Entities:  

Keywords:  Myocardial infarction; Primary percutaneous coronary intervention; ST-segment elevation; Stent thrombosis

Mesh:

Year:  2016        PMID: 27363417     DOI: 10.1007/s00059-016-4446-0

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  33 in total

1.  Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial.

Authors:  Helèn Boden; Bas L van der Hoeven; Su-San Liem; Jael Z Atary; Suzanne C Cannegieter; Douwe E Atsma; Marianne Bootsma; J Wouter Jukema; Katja Zeppenfeld; Pranobe V Oemrawsingh; Ernst E van der Wall; Martin J Schalij
Journal:  EuroIntervention       Date:  2012-01       Impact factor: 6.534

2.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

Authors:  Peter Wenaweser; Joost Daemen; Marcel Zwahlen; Ron van Domburg; Peter Jüni; Sophia Vaina; Gerrit Hellige; Keiichi Tsuchida; Cyrill Morger; Eric Boersma; Neville Kukreja; Bernhard Meier; Patrick W Serruys; Stephan Windecker
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

3.  Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison.

Authors:  Takashi Miyamoto; Tetsuya Ishikawa; Yosuke Nakano; Makoto Mutoh
Journal:  Cardiovasc Interv Ther       Date:  2016-03-15

4.  Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Martin Fahy; Helen Parise; Roxana Mehran
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

5.  Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience.

Authors:  Bruce Brodie; Yashashwi Pokharel; Nathan Fleishman; Adam Bensimhon; Grace Kissling; Charles Hansen; Sally Milks; Michael Cooper; Christopher McAlhany; Tom Stuckey
Journal:  JACC Cardiovasc Interv       Date:  2011-01       Impact factor: 11.195

6.  Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevation myocardial infarction: findings from the Guthrie Health Off-label Stent (GHOST) Registry.

Authors:  Sudhakar Sattur; Pam Orshaw; Judy Boura; Kishore J Harjai
Journal:  J Interv Cardiol       Date:  2012-02-10       Impact factor: 2.279

7.  Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).

Authors:  Jessica L Mega; Eugene Braunwald; Sabina A Murphy; Alexei N Plotnikov; Paul Burton; Robert Gabor Kiss; Alexander Parkhomenko; Michal Tendera; Petr Widimsky; C Michael Gibson
Journal:  J Am Coll Cardiol       Date:  2013-03-07       Impact factor: 24.094

8.  Low-dose colchicine for secondary prevention of cardiovascular disease.

Authors:  Stefan M Nidorf; John W Eikelboom; Charley A Budgeon; Peter L Thompson
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

9.  Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos).

Authors:  José M de la Torre-Hernández; Fernando Alfonso; Felipe Hernández; Jaime Elizaga; Marcelo Sanmartin; Eduardo Pinar; Iñigo Lozano; Jose M Vazquez; Javier Botas; Armando Perez de Prado; Jose M Hernández; Juan Sanchis; Juan M Ruiz Nodar; Alfredo Gomez-Jaume; Mariano Larman; Jose A Diarte; Javier Rodríguez-Collado; Jose R Rumoroso; Jose R Lopez-Minguez; Josepa Mauri
Journal:  J Am Coll Cardiol       Date:  2008-03-11       Impact factor: 24.094

10.  Recurrent myocardial infarction after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Authors:  Wouter J Kikkert; Loes P Hoebers; Peter Damman; Krystien V V Lieve; Bimmer E P M Claessen; Marije M Vis; Jan Baan; Karel T Koch; Robbert J de Winter; Jan J Piek; Jan G P Tijssen; Jose P S Henriques
Journal:  Am J Cardiol       Date:  2013-10-03       Impact factor: 2.778

View more
  1 in total

1.  When More Means Less: The Prognosis of Recurrent Acute Myocardial Infarctions.

Authors:  Ygal Plakht; Harel Gilutz; Arthur Shiyovich
Journal:  J Clin Med       Date:  2021-12-15       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.